Endobronchial Ultrasound Biopsy Market (2025 - 2033)

Endobronchial Ultrasound Biopsy Market Summary

The global endobronchial ultrasound biopsy market size was estimated at USD 728.6 million in 2024 and is projected to reach USD 1,186.5 million by 2033, growing at a CAGR of 6.30% from 2025 to 2033. This growth can be attributed to the rising prevalence of cancer, increasing technological advancements in endobronchial ultrasound (EBUS) technology, the growing geriatric population, the growing prevalence of respiratory diseases, and the increasing adoption of minimally invasive procedures.

According to the WHO, the global elderly population aged 60 years and above is expected to increase from around 1.1 billion in 2021 to 1.4 billion in 2030. The increasing prevalence of lung cancer drives market growth as it is one of the leading causes of cancer-related deaths worldwide, with rising incidence rates attributed to factors such as smoking, air pollution, and occupational hazards. For instance, the American Cancer Society projects that in 2025, there will be approximately 226,650 new lung cancer cases in the U.S., with 110,680 cases occurring in men and 115,970 in women. In addition, it is estimated that there will be around 124,730 deaths due to lung cancer, comprising 64,190 men and 60,540 women. As early and accurate diagnosis is critical for improving patient outcomes, there is a growing demand for minimally invasive procedures such as EBUS-guided biopsy. This technique allows for precise sampling of lymph nodes and lung lesions, allowing early-stage detection and staging of lung cancer.

Furthermore, the rising prevalence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD), tuberculosis, and others, significantly contributes to the market growth. As these conditions become more widespread due to factors such as smoking, air pollution, and aging populations, the demand for minimally invasive diagnostic procedures has increased. In addition, advancements in EBUS technology, including better imaging resolution and real-time needle guidance, enhance diagnostic efficiency and further improve its adoption among healthcare providers.

Market Concentration & Characteristics

The chart below illustrates the relationship between market concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, impact of regulations, level of partnerships & collaborations activities, degree of innovation, and regional expansion. For instance, the market is slightly fragmented, with many product & service providers entering the market. The degree of innovation, the level of partnerships & collaboration activities, and the impact of regulations on the industry are high. However, moderate growth was observed in regional expansion.

The endobronchial ultrasound biopsy (EBUS) industry is witnessing significant innovation as market players introduce advanced products and accessories to meet the increasing demand for effective EBUS procedures and improve patient outcomes. For instance, in September 2023, Broncus Medical launched the BioStar Transbronchial Aspiration Needle (TBNA) for minimally invasive lung cancer diagnostics. It integrates with endobronchial ultrasound procedures, offering various gauge options and an advanced design for reduced tissue disruption and improved accuracy.

The endobronchial ultrasound industry market is expected to witness significant partnership and collaboration activities from companies seeking to enhance technological innovation and expand their market presence. Moreover, collaborations with healthcare providers will drive adoption by promoting minimally invasive procedures for lung cancer and respiratory disease diagnosis.

Regulations are critical in shaping the endobronchial ultrasound biopsy industry, influencing product approvals, market access, and adoption rates. Stringent regulatory requirements from the FDA, EMA, and others ensure product safety and efficacy. Compliance with evolving guidelines related to medical device classification, clinical trial requirements, and post-market surveillance is essential for market entry and expansion. However, excessive regulatory burdens can limit competition, potentially driving up costs for healthcare providers.

Traditional diagnostic methods such as conventional bronchoscopy, Transthoracic Needle Aspiration (TTNA), and surgical biopsy are potential substitutes for the endobronchial ultrasound biopsy industry. While TTNA offers direct access to peripheral lung lesions, it carries a higher risk of pneumothorax. Similarly, surgical biopsy, including mediastinoscopy, provides a definitive diagnosis but is invasive, costly, and associated with longer recovery times.

The endobronchial ultrasound biopsy industry is witnessing growth across various regions, driven by increasing lung cancer prevalence, advancements in minimally invasive diagnostic techniques, and improved healthcare infrastructure. In addition, favorable regulatory approvals and strategic partnerships between global manufacturers and local distributors are accelerating market penetration.

Moreover, market players are expanding their production capabilities in various regions to meet the increasing demand for these products. For instance, in October 2024, GE Healthcare announced the expansion of its production of medical imaging equipment in Waukesha County, Wisconsin, U.S., including MRI and ultrasound machines, to meet rising demand. The expansion aims to enhance healthcare delivery and innovation, responding to the growing need for advanced tools in hospitals and clinics worldwide.

Case Study:

Successful Diagnosis of Peripheral Pulmonary Nodule Using Advanced Radial EBUS-Guided Bronchoscopy:

Overview:

A 74-year-old female was referred for evaluation of a 1.2 cm left upper lobe (LUL) pulmonary nodule discovered during routine imaging surveillance for a suspected thymoma. Thoracic Surgery requested a tissue biopsy prior to considering surgical resection. A PET-CT scan showed no abnormalities apart from the LUL nodule, prompting the scheduling of a bronchoscopy procedure.

Outcome:

Rapid on-site cytological evaluation (ROSE) of the brushing confirmed non-small cell carcinoma, and subsequent histopathology identified the lesion as squamous cell carcinoma. This case highlights the value of advanced bronchoscopic techniques in safely reaching peripheral pulmonary nodules. The smaller diameter BF-P190 enabled navigation through narrow airways, while the Guide Sheath served as a stable conduit for repeated sampling. The rotation of the bronchoscope's insertion tube also helped reduce operator fatigue, facilitating efficient and accurate biopsy.

Product Insights

The EBUS scopes segment dominated the market in 2024 with the largest revenue share of 33.0%, owing to the demand for minimally invasive lung cancer and mediastinal lymphadenopathy diagnostic procedures. Moreover, technological innovations in EBUS scopes, such as high-frequency ultrasound probes, enhanced visualization, and improved needle design, are accelerating their adoption. For instance, in September 2024, FUJIFILM Healthcare Europe announced the ARIETTA 750 FF ENDO ultrasound system, compatible with various ultrasound endoscopes and bronchoscopes. It features advanced imaging technologies such as eFocusing and Detective Flow Imaging, enhancing diagnostic capabilities.

EBUS needles is anticipated to witness the fastest growth over the forecast period. As healthcare providers prioritize early and accurate diagnosis, the demand for EBUS-guided transbronchial needle aspiration procedures is increasing. Technological advancements, including improved needle design for better sample collection and reduced patient discomfort, further contribute to the segment growth. Market players focus on product innovations, such as flexible and fine-gauge needles, to enhance procedural efficiency and diagnostic capabilities.

Procedure Insights

The EBUS-Transbronchial Needle Aspiration (EBUS-TBNA) segment captured the largest revenue share of 61.1% in 2024. Clinicians and healthcare providers have shifted toward EBUS-TBNA due to its higher diagnostic yield, reduced patient discomfort, and lower complication rates compared to conventional mediastinoscopy. In addition, growing preference for ambulatory and outpatient procedures is also driving demand, as EBUS-TBNA allows same-day discharge, improving hospital efficiency and cost-effectiveness.

EBUS-guided biopsy segment is expected to grow at the fastest CAGR of 5.74% during the forecast period. Advancements in minimally invasive techniques have made EBUS-guided biopsy a preferred alternative to traditional mediastinoscopy, reducing patient risk and hospital stay. Healthcare providers prefer this procedure owing to its better diagnostic outcomes and safety, driving its adoption in hospitals and specialized diagnostic centres. Moreover, expanding applications beyond oncology, including infectious and inflammatory disease diagnoses, further contribute to its increasing preference in healthcare facilities.

End Use Insights

The hospitals segment accounted for the largest revenue share of 42.2% in 2024. Hospitals prioritize EBUS technology due to its high diagnostic accuracy and reduced patient risk compared to traditional biopsy methods. The integration of advanced imaging and robotic-assisted bronchoscopy is further enhancing procedural efficiency. In addition, hospitals benefit from favorable reimbursement policies and government funding for advanced diagnostic technologies, making them the primary adopters of EBUS biopsy systems.

The ambulatory surgical centers segment is expected to grow fastest over the forecast period. Ambulatory surgical centers offer a lower-cost alternative to hospitals while maintaining high procedural efficiency, making them an attractive option for patients and payers. Advancements in portable ultrasound technology and improved reimbursement policies for outpatient settings have enabled these facilities to integrate EBUS procedures.

Regional Insights

North America dominated the endobronchial ultrasound biopsy market in 2024 and accounted for a revenue share of 29.18%, owing to the increasing prevalence of respiratory diseases, such as lung cancer, and the rising demand for minimally invasive diagnostic techniques. Countries in North America have prioritized early detection and staging of lung cancer, supported by clinical guidelines that endorse EBUS-guided procedures, especially Convex Probe EBUS (CP-EBUS), for mediastinal and hilar lymph node evaluation. The widespread use of low-dose CT screening programs in the U.S. and Centers for Medicare & Medicaid Services (CMS) reimbursement policies has encouraged hospitals and health systems to adopt EBUS as a standard diagnostic tool.

U.S. Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in the U.S. is being driven by the increasing prevalence of respiratory diseases, which is one of the leading causes of death in the country. According to the Centers for Disease Control and Prevention (CDC), around 4.3% of adults aged 18 and over were estimated to be living with COPD, emphysema, or chronic bronchitis in 2023. As more patients seek early diagnosis and treatment, the demand for minimally invasive procedures such as EBUS is expected to grow over the forecast period.

Europe Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Europe is witnessing notable growth, primarily driven by the rising prevalence of lung cancer and increasing demand for minimally invasive diagnostic tools. For instance, according to Eurostat in 2021, 226,500 people died due to lung cancer in Europe, resulting in around 19.8% of all deaths by cancer. EBUS has become a preferred diagnostic modality across many European healthcare systems, particularly because it can obtain real-time images and facilitate precise needle aspiration of lymph nodes and masses in the mediastinum and lungs. The aging population and heightened awareness regarding early lung cancer detection are also fueling the demand for such advanced procedures.

The UK endobronchial ultrasound biopsy marketis experiencing steady growth, largely driven by the increasing incidence of lung cancer and the country’s focus on early and accurate diagnosis of thoracic diseases. The National Health Service (NHS) has placed significant emphasis on early detection of lung abnormalities, which has led to the greater adoption of minimally invasive diagnostic techniques like EBUS. Convex Probe EBUS (CP-EBUS) and Radial Probe EBUS (RP-EBUS) are now integral tools in tertiary care centers and specialist hospitals for mediastinal staging and diagnosing peripheral lung lesions.

The endobronchial ultrasound biopsy market in Germany is experiencing strong momentum, driven by several converging factors, including the launch of the national low-dose CT (LDCT) lung cancer screening program targeting high-risk individuals, marking a major milestone in early cancer detection in July 2024. The initiative includes double-reading mandatory review of all scans by two radiologists (uses AI support and focuses on individuals aged 50-75 with significant smoking histories. This will naturally increase referrals for diagnostic confirmation via EBUS procedures in academic and specialized centers across Germany.

Asia Pacific Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Asia-Pacific is expected to grow significantly during the forecast period, driven by the increasing incidence of lung cancer, greater access to healthcare services, and a rising preference for minimally invasive procedures. Countries such as Japan, Australia, and New Zealand are at the forefront of adopting EBUS technologies, especially Convex Probe EBUS (CP-EBUS) and Radial Probe EBUS (RP-EBUS). Clinicians and healthcare systems are increasingly looking for alternatives to surgical biopsies, with real-world clinical evidence playing a crucial role in shaping adoption trends.

Japan endobronchial ultrasound biopsy market is witnessing growth driven by the rising incidence of lung cancer, which remains one of the leading causes of cancer-related deaths in the country. Increasing demand for minimally invasive diagnostic procedures further supports market expansion, as EBUS offers accurate tissue sampling with reduced patient risk compared to traditional surgical biopsies. In addition, the growing adoption of advanced imaging technologies in hospitals, coupled with government initiatives to strengthen early cancer detection programs, is accelerating the uptake of EBUS systems. Rising healthcare expenditure and the presence of specialized centers are also contributing to a sustained market.

The endobronchial ultrasound biopsy market in Chinais driven by the rising incidence of lung cancer and the country's ongoing healthcare modernization efforts. With increased medical technology and infrastructure investments, China's healthcare system is significantly evolving. The government has also made efforts to improve the accessibility of advanced medical procedures, encouraging the widespread use of diagnostic tools such as EBUS. As more hospitals and medical centers across China integrate EBUS into their lung cancer treatment procedures, the market for endobronchial ultrasound biopsy in China is expected to grow over the forecast period.

Latin America Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in Latin America is driven by the increasing prevalence of lung cancer and the demand for more advanced diagnostic solutions across the region. Healthcare systems in Latin America are increasingly focused on reducing the costs associated with invasive surgeries and lengthy hospital stays, indicating EBUS as a cost-effective solution. The rising cancer rates, the adoption of advanced medical technologies, and a growing emphasis on early and accurate diagnosis are expected to drive the market growth over the forecast period.

Middle East & Africa Endobronchial Ultrasound Biopsy Market Trends

The endobronchial ultrasound biopsy market in the Middle East and Africa is attributed to the development of health amenities and increased funding for medical research and technology. Further, the GCC countries are new to clinical research, but with technological advancements and increasing digitization, they are overcoming technological challenges and witnessing significant growth.

Key Endobronchial Ultrasound Biopsy Company Insights

The Endobronchial Ultrasound (EBUS) Biopsy market is shifting towards consolidation. Key players such as Olympus Corporation, FUJIFILM Holdings, Boston Scientific, Cook Group, and PENTAX Medical dominate the market with comprehensive EBUS-biopsy systems, needles, and imaging platforms. These companies are actively expanding their portfolios through product innovation, clinical collaborations, and expanded distribution networks to strengthen their global presence. Meanwhile, emerging firms like Praxis Medical, ACE Medical Devices Pvt. Ltd., and Medi-Globe Technologies are gaining visibility by introducing cost-effective, single-use biopsy tools and motorized needle systems tailored for precision lung diagnostics.

Recent Developments

• In January 2025, Olympus America acquired the distribution business from Sur Medical SpA in Chile, enabling Olympus Latin America to now directly sell, distribute, and service its full medical technology portfolio in-market through its newly established local subsidiary.

This strategic acquisition of Surmedical’s well-established and successful distribution business for Olympus technologies gives Olympus a very strong foundation for operations in Chile.”

- Jose Gaston, President of Olympus Latin America.

• In September 2024, FUJIFILM Healthcare Europe GmbH announced that its ARIETTA 750 FF ENDO ultrasound system is compatible with several ultrasound endoscopes and a linear bronchoscope. This system features advanced technologies such as “eFocusing” for improved image clarity and “Carving Imaging” for enhanced visualization.

• In September 2024, FUJIFILM Healthcare Europe GmbH announced that its ARIETTA 750 FF ENDO ultrasound system is compatible with several ultrasound endoscopes and a linear bronchoscope. This system features advanced technologies such as “eFocusing” for improved image clarity and “Carving Imaging” for enhanced visualization.

• In September 2022, DCC plc acquired Medi‑Globe Technologies GmbH, intending to expand its footprint in single-use minimally invasive procedures across Europe.

We are delighted to welcome Medi-Globe into the DCC Group. The synergistic acquisition of Medi-Globe significantly expands and enhances DCC Vital’s position in the medical devices sector. It will create a leading international platform in single-use medical devices for minimally invasive procedures, with strong product development capability.”

Donal Murphy, Chief Executive of DCC plc

Endobronchial Ultrasound Biopsy Market